NCT01946243View on ClinicalTrials.gov

The Feasibility of Florbetapir Quantitation

PHASE4CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Alzheimers Disease
Interventions
DRUG

Florbetapir F18

No Florbetapir F 18 will be administered in this study.

Trial Locations (1)

19103

Research Site, Philadelphia

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY